Gen Kuroyanagi

Gen Kuroyanagi

Auto-generated profile, based on publicly available information

Gen Kuroyanagi

Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
NKN. Kamiya
N. Kamiya
GKG. Kuroyanagi
G. Kuroyanagi
OAO. Aruwajoye
O. Aruwajoye
HKHarry K.W. Kim
Harry K.W. Kim

1 November 2018 in Bone
Verified
Journal Article
Closed access
GKGen Kuroyanagi
Gen Kuroyanagi
NANaga Suresh Adapala
Naga Suresh Adapala
RYRyosuke Yamaguchi
Ryosuke Yamaguchi
NKNobuhiro Kamiya
Nobuhiro Kamiya
ZDZhuo Deng
Zhuo Deng
HKHarry K.W. Kim
Harry K.W. Kim

Verified
Journal Article
Open access
PDF file
GKGen Kuroyanagi
Gen Kuroyanagi
Yoshinobu HiroseYoshinobu Hirose
Yoshinobu Hirose
NYNaohiro Yamamoto
Naohiro Yamamoto
RMRie Matsushima-Nishiwaki
Rie Matsushima-Nishiwaki
ANAkira Nakakami
Akira Nakakami
HTHaruhiko Tokuda
Haruhiko Tokuda
It is firmly established that resveratrol, a natural food compound abundantly found in grape skins and red wine, has beneficial properties for human health. In the present study, we investigated the effect of basic fibroblast growth factor (FGF-2) on osteoprotegerin (OPG) synthesis in osteoblast-like MC3T3-E1 cells and whether resveratrol affects the OPG synthesis. FGF-2 stimulated both the OPG release and the expression of OPG mRNA. Resveratrol significantly suppressed the FGF-2-stimulated OPG release and the mRNA levels of OPG. SRT1720, an activator of SIRT1, reduced the FGF-2-induced OPG release and the OPG mRNA expression. PD98059, an inhibitor of upstream kinase activating p44/p42 mitogen-activated protein (MAP) kinase, had little effect on the FGF-2-stimulated OPG release. On the other hand, SB203580, an inhibitor of p38 MAP kinase, SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and Akt inhibitor suppressed the OPG release induced by FGF-2. Resveratrol failed to affect the FGF-2-induced phosphorylation of p44/p42 MAP kinase, p38 MAP kinase or SAPK/JNK. The phosphorylation of Akt induced by FGF-2 was significantly suppressed by resveratrol or SRT1720. These findings strongly suggest that resveratrol down-regulates FGF-2-stimulated OPG synthesis through the suppression of the Akt pathway in osteoblasts and that the inhibitory effect of resveratrol is mediated at least in part by SIRT1 activation.

1 June 2021 in Injury
Verified
Journal Article
Closed access
TUTakuya Usami
Takuya Usami
NTNaoya Takada
Naoya Takada
HSHiroaki Sakai
Hiroaki Sakai
SEShinichiro Endo
Shinichiro Endo
ISIsato Sekiya
Isato Sekiya
GKGen Kuroyanagi
Gen Kuroyanagi

12 February 2021 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
RYRyosuke Yamaguchi
Ryosuke Yamaguchi
NKNobuhiro Kamiya
Nobuhiro Kamiya
GKGen Kuroyanagi
Gen Kuroyanagi
YRYinshi Ren
Yinshi Ren
HKHarry K.W. Kim
Harry K.W. Kim

2 August 2023 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
GKGen Kuroyanagi
Gen Kuroyanagi
NKNobuhiro Kamiya
Nobuhiro Kamiya
RYRyosuke Yamaguchi
Ryosuke Yamaguchi
HKHarry K.W. Kim
Harry K.W. Kim
Juvenile ischemic osteonecrosis (JIO) of the femoral head is one of the most serious hip disorders causing a permanent deformity of the femoral head in childhood. We recently reported that interleukin 6 (IL-6) is significantly increased in the hip synovial fluid of patients with JIO and that articular chondrocytes are primary source of IL-6. Adolescent JIO is particularly challenging to treat and has poor outcome. This study determined if IL-6 receptor blockade prevents bone loss and improves the bone healing in adolescent JIO. Adolescent mice (12-week-old) surgically induced with JIO were treated with either saline or MR16-1, an IL-6 receptor blocker. Micro-CT assessment showed significantly increased bone volume (p ​< ​0.001, Cohen's d ​= ​2.0) and trabecular bone thickness (p ​< ​0.001, d ​= ​2.3) after the MR16-1 treatment. Histomorphometric assessment showed significantly increased osteoblast number (p ​< ​0.01, d ​= ​2.3), bone formation rate (p ​< ​0.01, d ​= ​4.3), and mineral apposition rate (p ​< ​0.01, d ​= ​4.1) after the MR16-1 treatment. The number of osteoclasts was unchanged. Histologic assessment showed significantly increased revascularization (p ​< ​0.01) and restoration of the necrotic marrow with new hematopoietic bone marrow (p ​< ​0.01). Vascular endothelial growth factor (VEGF) expression was increased in the revascularized area and the articular cartilage, and in the cultured chondrocytes treated with IL-6 receptor inhibitor. IL-6 blockade in adolescent mice with JIO enhanced bone formation and revascularization. The findings suggest IL-6 receptor blocker as a potential medical therapy for adolescent JIO.